<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Candel Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/candel-therapeutics-inc</link>
<description>Latest news and press releases for Candel Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 12:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/candel-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835519978dffbe2df0e7afb.webp</url>
<title>Candel Therapeutics Inc</title>
<link>https://6ix.com/company/candel-therapeutics-inc</link>
</image>
<item>
<title>Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer</title>
<link>https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-announces-commercialization-agreement-with-eversana-to-support-potential-us-launch-of-aglatimagene-besadenovec-in-localized-prostate-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-announces-commercialization-agreement-with-eversana-to-support-potential-us-launch-of-aglatimagene-besadenovec-in-localized-prostate-cancer</guid>
<pubDate>Wed, 29 Apr 2026 12:05:00 GMT</pubDate>
<description>EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA submission in Q4 2026 NEEDHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to help patients with cancer, today announced that it entered into a product commercialization agreement (the “Agreement”) with E</description>
</item>
<item>
<title>Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors</title>
<link>https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-reports-extended-survival-tail-observed-in-trial-of-aglatimagene-besadenovec-can-2409-in-advanced-non-small-cell-lung-cancer-patients-with-inadequate-response-to-immune-checkpoint-inhibitors</link>
<guid isPermaLink="true">https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-reports-extended-survival-tail-observed-in-trial-of-aglatimagene-besadenovec-can-2409-in-advanced-non-small-cell-lung-cancer-patients-with-inadequate-response-to-immune-checkpoint-inhibitors</guid>
<pubDate>Tue, 17 Mar 2026 12:05:00 GMT</pubDate>
<description>Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with aglatimagene besadenovec (aglatimagene or CAN-2409) surviving beyond 24 months, despite prior inadequate response to immune checkpoint inhibitors (ICI) and multiple adverse baseline prognostic factors.Among the patients surviving beyond 24 months and with PD-L1 status available, (17/20) 85% had baselin</description>
</item>
<item>
<title>Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights</title>
<link>https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-highlights-2</link>
<guid isPermaLink="true">https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-highlights-2</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic,</description>
</item>
<item>
<title>Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting</title>
<link>https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-to-present-new-data-after-extended-follow-up-from-randomized-phase-3-trial-of-aglatimagene-besadenovec-in-localized-prostate-cancer-at-the-american-urological-association-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-to-present-new-data-after-extended-follow-up-from-randomized-phase-3-trial-of-aglatimagene-besadenovec-in-localized-prostate-cancer-at-the-american-urological-association-2026-annual-meeting</guid>
<pubDate>Mon, 09 Mar 2026 12:05:00 GMT</pubDate>
<description>NEEDHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for oral presentation in the Practice-changing, Paradigm-shifting Clinical Trials in Urology session, as part of the American Urological Association (AUA) 2026 Annual Meeting Plenary Program being held i</description>
</item>
<item>
<title>Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston</title>
<link>https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-to-present-at-td-cowens-46th-annual-health-care-conference-in-boston</link>
<guid isPermaLink="true">https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-to-present-at-td-cowens-46th-annual-health-care-conference-in-boston</guid>
<pubDate>Tue, 24 Feb 2026 13:05:00 GMT</pubDate>
<description>NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will present at TD Cowen’s 46th Annual Health Care Conference, being held on March 2-4, 2026 in Boston, MA. Presentation Details: Date: Tuesday</description>
</item>
<item>
<title>Candel Therapeutics Announces Pricing of Public Offering</title>
<link>https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-announces-pricing-of-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-announces-pricing-of-public-offering</guid>
<pubDate>Fri, 20 Feb 2026 02:40:00 GMT</pubDate>
<description>NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the pricing of an underwritten public offering of 18,348,624 shares of its common stock at a price to the public of $5.45 per share. The gross proceeds to Candel from the offering are expected to be $100 million, before deducting unde</description>
</item>
<item>
<title>Candel Therapeutics Announces Proposed $100 Million Public Offering</title>
<link>https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-announces-proposed-dollar100-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-announces-proposed-dollar100-million-public-offering</guid>
<pubDate>Thu, 19 Feb 2026 21:05:00 GMT</pubDate>
<description>NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the launch of an underwritten public offering of $100 million of its common stock. Candel also intends to grant the underwriters a 30-day option to purchase up to an additional $15 million in shares of its common stock on the same ter</description>
</item>
<item>
<title>Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer</title>
<link>https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-announces-dollar100m-royalty-funding-agreement-with-rtw-to-support-the-potential-launch-of-aglatimagene-besadenovec-can-2409-in-localized-prostate-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-announces-dollar100m-royalty-funding-agreement-with-rtw-to-support-the-potential-launch-of-aglatimagene-besadenovec-can-2409-in-localized-prostate-cancer</guid>
<pubDate>Thu, 19 Feb 2026 21:01:00 GMT</pubDate>
<description>RTW committed $100M in U.S. launch funding, subject to U.S. Food and Drug Administration (FDA) approval of aglatimagene besadenovec (aglatimagene or CAN-2409) for intermediate- to high-risk localized prostate cancer Royalties based on annual net sales of aglatimagene in the U.S.Funds will strengthen the Company’s balance sheet for potential U.S. commercial launch of aglatimagene in intermediate- to high-risk localized prostate cancer NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Thera</description>
</item>
<item>
<title>Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit</title>
<link>https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-present-7th-annual-130500136</link>
<guid isPermaLink="true">https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-present-7th-annual-130500136</guid>
<pubDate>Wed, 11 Feb 2026 13:05:00 GMT</pubDate>
<description>NEEDHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Francesca Barone, M.D., Ph.D., Candel’s Chief Scientific Officer, will present data and participate in multiple sessions at the 7th Annual Glioblastoma Drug Development Summit, taking place February 17-19, 2026 in Boston, Massach</description>
</item>
<item>
<title>Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-announces-inducement-grants-210500730</link>
<guid isPermaLink="true">https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-announces-inducement-grants-210500730</guid>
<pubDate>Mon, 02 Feb 2026 21:05:00 GMT</pubDate>
<description>NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on January 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 6,600 shares of the Company’s common stock, with a per share exerci</description>
</item>
<item>
<title>Candel Therapeutics to Host Virtual R&D Event on December 5, 2025</title>
<link>https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-host-virtual-r-210500352</link>
<guid isPermaLink="true">https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-host-virtual-r-210500352</guid>
<pubDate>Mon, 17 Nov 2025 21:05:00 GMT</pubDate>
<description>NEEDHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced it will host a virtual Research and Development (R&D) Event from 11:00 am – 1:45 pm ET on Friday, December 5, 2025. Candel’s R&D Day will include presentations and panel discussions from its executive leadership, clinical investigator</description>
</item>
<item>
<title>Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights</title>
<link>https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-reports-third-quarter-132500270</link>
<guid isPermaLink="true">https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-reports-third-quarter-132500270</guid>
<pubDate>Thu, 13 Nov 2025 13:25:00 GMT</pubDate>
<description>Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved prostate cancer-specific disease-free survival (DFS), independent of radiation therapy modality utilized Company plans to initiate pivotal phase 3 clinical trial of CAN-2409 in patients with metastatic, non-squamous, non-small cell lung cancer (NSCLC) and progressive disease, despite immune checkpoint inhi</description>
</item>
<item>
<title>Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors</title>
<link>https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-showcases-immunotherapy-leadership-140000537</link>
<guid isPermaLink="true">https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-showcases-immunotherapy-leadership-140000537</guid>
<pubDate>Tue, 04 Nov 2025 14:00:00 GMT</pubDate>
<description>Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and CEO, will present the phase 3 clinical trial of CAN-2409 in newly diagnosed, localized prostate cancer, which achieved its primary endpoint, supported by secondary endpoints Poster presentation: Daniel Sterman M.D., Professor at NYU Langone Health will present ‘Multi-omics analysis of CAN-2409 in non-small cell lung cancer (NSCL</description>
</item>
<item>
<title>Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London</title>
<link>https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-present-jefferies-global-130500110</link>
<guid isPermaLink="true">https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-present-jefferies-global-130500110</guid>
<pubDate>Mon, 03 Nov 2025 13:05:00 GMT</pubDate>
<description>NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference, being held on November 17-20, 2025 in London, United Kingdom. Presentation Details:</description>
</item>
<item>
<title>Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board</title>
<link>https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-appoints-leading-systems-120500080</link>
<guid isPermaLink="true">https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-appoints-leading-systems-120500080</guid>
<pubDate>Thu, 16 Oct 2025 12:05:00 GMT</pubDate>
<description>NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Bali Pulendran, Ph.D. to Candel’s Research Advisory Board (RAB). Dr. Pulendran, an internationally recognized expert in systems immunology and vaccinology, who has pioneered the use of systems approaches to understa</description>
</item>
<item>
<title>Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.</title>
<link>https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-enters-130-million-121000589</link>
<guid isPermaLink="true">https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-enters-130-million-121000589</guid>
<pubDate>Tue, 14 Oct 2025 12:10:00 GMT</pubDate>
<description>$50 million drawn down at closing, with access to up to an additional $80 millionStrengthens Company’s financial position; enables initiation of phase 3 clinical trial of CAN-2409 in non-small cell lung cancer (NSCLC)Provides non-dilutive capital and additional financial flexibility ahead of a potential commercial launch in early localized prostate cancer NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharma</description>
</item>
<item>
<title>Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine</title>
<link>https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-announces-positive-interim-120500833</link>
<guid isPermaLink="true">https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-announces-positive-interim-120500833</guid>
<pubDate>Tue, 14 Oct 2025 12:05:00 GMT</pubDate>
<description>NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced encouraging interim data from its ongoing phase 1b clinical trial of CAN-3110 (linoserpaturev) in recurrent glioblastoma, and a publication in the high-impact scientific journal Science Translational Medicine. The research detailed in</description>
</item>
<item>
<title>Candel Therapeutics to Present at the SITC 2025 Annual Meeting</title>
<link>https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-present-sitc-2025-130500026</link>
<guid isPermaLink="true">https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-present-sitc-2025-130500026</guid>
<pubDate>Fri, 03 Oct 2025 13:05:00 GMT</pubDate>
<description>NEEDHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present insights from its enLIGHTEN™ Discovery Platform, and additional data from the CAN-2409 (aglatimagene besadenovec) program in non-small cell lung cancer (NSCLC), through two accepted poster presentations at the</description>
</item>
<item>
<title>Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025</title>
<link>https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-presents-phase-3-120500513</link>
<guid isPermaLink="true">https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-presents-phase-3-120500513</guid>
<pubDate>Mon, 29 Sep 2025 12:05:00 GMT</pubDate>
<description>CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to placebo in patients treated with either conventional or moderate hypofractionated radiotherapy with curative intent, independent of the specific modality of radiation therapy used NEEDHAM, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biolo</description>
</item>
<item>
<title>Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025</title>
<link>https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-present-phase-3-120500704</link>
<guid isPermaLink="true">https://6ix.com/company/candel-therapeutics-inc/news/candel-therapeutics-present-phase-3-120500704</guid>
<pubDate>Wed, 17 Sep 2025 12:05:00 GMT</pubDate>
<description>NEEDHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for an oral presentation at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place from September 27 to October 1, 2025, in San Francisco, CA. The oral presentation will fe</description>
</item>
</channel>
</rss>